# Changes of serum inflammatory markers and immune function in children with bronchial asthma complicated with mycoplasma pneumoniae infection before and after treatment and their clinical significance

**Authors:** Xiao-jun Shi, Hui-min Tian, Cai-xia Li, Jin-kai Wei

PMC · DOI: 10.12669/pjms.41.5.11067 · Pakistan Journal of Medical Sciences · 2025-05-01

## TL;DR

The study examines how inflammation and immune markers in children with asthma and mycoplasma infection change before and after treatment.

## Contribution

The study identifies specific immune and inflammatory markers that improve after treatment in children with a combined asthma and mycoplasma infection.

## Key findings

- Before treatment, immune and inflammatory markers like IL-2, IL-4, and SAA were significantly different in the experimental group compared to the control group.
- After treatment, most inflammatory and immune markers improved significantly in the experimental group, except for PCT.
- The results suggest these markers could help in diagnosing and assessing treatment effectiveness for the condition.

## Abstract

To evaluate the changes of serum inflammatory markers and immune function in children with bronchial asthma complicated with Mycoplasma pneumoniae infection before and after treatment.

This was a retrospective study. Thirty children with bronchial asthma complicated with mycoplasma pneumoniae infection were selected as the experimental group and 30 healthy children as the control group at Baoding First Central Hospital from December 2022 to December 2023. The levels of inflammatory markers interleukin-2(IL-2), interleukin-4(IL-4), Serum Amyloid A(SAA), Procalcitonin(PCT), immune markers immunoglobulin A(IgA), immunoglobulin G(IgG), immunoglobulin M(IgM) and CD4+ were detected before and after treatment, and the changes were compared with those of the control group.

Compared with the control group before treatment, the levels of immune markers, inflammatory markers IL-2, IL-4 and SAA in the experimental group were significantly different (p < 0.05). However, there was no significant difference between the two groups in PCT (p > 0.05) level. In the experimental group, except PCT, the levels of other inflammatory markers and immune markers were significantly improved after treatment, and the difference was statistically significant (P < 0.05).

Inflammatory markers and immune function of children with bronchial asthma complicated with Mycoplasma pneumoniae infection were abnormal to a certain extent, and the improvement was obvious after treatment. The result may have certain reference value for diagnosing the disease and determining its treatment effects.

## Linked entities

- **Proteins:** IL2 (interleukin 15), IL4 (interleukin 4), CD4 (CD4 molecule)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, SAA [NCBI Gene 6287], CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, UROD (uroporphyrinogen decarboxylase) [NCBI Gene 7389] {aka PCT, UPD}
- **Diseases:** bronchial asthma (MESH:D001249), Mycoplasma pneumoniae infection (MESH:D011019), Inflammatory (MESH:D007249)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12130944/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12130944/full.md

---
Source: https://tomesphere.com/paper/PMC12130944